NLS PHARMACEUTICS LTD (NLSP) Forecast, Price Target & Analyst Ratings

NASDAQ:NLSPCH1384053976

Current stock price

0.762 USD
+0.02 (+2.97%)
At close:
1.08 USD
+0.32 (+41.73%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NLS PHARMACEUTICS LTD (NLSP).

Forecast Snapshot

Consensus Price Target

Price Target
N/A
N/A

Next Earnings Forecast

Earnings Estimate
Release Date
N/A

ChartMill Buy Consensus

Rating
43.33%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
N/A
Upside
N/A
From current price of $0.76 to mean target of N/A, Based on 6 analyst forecasts
Low
N/A
Median
N/A
High
N/A

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

Analyst Ratings & History

Current Analyst Ratings

NLSP Current Analyst RatingNLSP Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5

Analyst Ratings History

NLSP Historical Analyst RatingsNLSP Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
43.33%
NLSP was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about NLSP.
In the previous month the buy percentage consensus was at a similar level.
NLSP was analyzed by 6 analysts. More opinions would make the average more meaningful.

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2023-09-14Maxim GroupDowngrade Buy -> Hold
2022-12-08Maxim GroupUpgrade Hold -> Buy
2022-11-08Maxim GroupDowngrade Buy -> Hold
2022-09-06Laidlaw & Co.Initiate Buy
2021-03-12Brookline CapitalInitiate Buy
2021-03-03Maxim GroupInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2017 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
YoY % growth
NLSP revenue by date.NLSP revenue by date.
N/A
EBITDA
YoY % growth
NLSP ebitda by date.NLSP ebitda by date.
N/AN/AN/AN/A-11.85M-15.47M
-30.55%
-11.796M
23.75%
-3.633M
69.20%
N/A
EBIT
YoY % growth
NLSP ebit by date.NLSP ebit by date.
-5.77M-3.45M
40.21%
-4.2M
-21.74%
-2.3M
45.24%
-11.86M
-415.65%
-15.48M
-30.52%
-11.807M
23.73%
-3.636M
69.20%
N/A
-649.06%
Operating Margin
NLSP operating margin by date.NLSP operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
NLSP eps by date.NLSP eps by date.
N/AN/AN/AN/AN/A
-958.82%
N/A
-1.24%
N/A
93.05%
N/A
-5.26%
N/A
97.19%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

NLSP Yearly EPS VS EstimatesNLSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A

NLS PHARMACEUTICS LTD / NLSP Forecast FAQ